Back to results
US 2012/0258962 A1Published application
1,3-oxazines as bace1 and/or bace2 inhibitors
AssigneeHoffmann-La Roche Inc.
InventorsHans Hilpert, Wolfgang Wostl
Life of this patent
Estimating the term…
Abstract
The present invention provides 4-(3-Amino-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.
Claims26
A compound of formula I,
- wherein
- R1 is selected from the group consisting of
- hydrogen,
- halogen, and
- C1-6-alkyl;
- R2 is selected from the group consisting of
- hydrogen,
- C1-6-alkyl, and
- halogen-C1-3-alkyl;
- R3 is selected from the group consisting of
- hydrogen and
- C1-6-alkyl;
- R4 is selected from the group consisting of
- halogen,
- C1-6-alkyl, and
- halogen-C1-6-alkoxy;
- R5 is —C(═O)—R6;
- and
- R6 is selected from the group consisting of
- heteroaryl,
- heteroaryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-6-alkoxy, C3-6-cycloalkyl-C1-6-alkyl, C3-6-cycloalkyl-C2-6-alkynyl, C2-6-alkynyl-C1-6-alkoxy and C1-6-alkyl,
- C3-6-cycloalkyl,
- C3-6-cycloalkyl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, hydroxy, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl,
- heterocyclyl, and
- heterocyclyl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl;
- or a pharmaceutically acceptable salt thereof.
23 more elements
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
- wherein
- R1 is selected from the group consisting of
- hydrogen,
- halogen, and
- C1-6-alkyl;
- R2 is selected from the group consisting of
- hydrogen,
- C1-6-alkyl, and
- halogen-C1-3-alkyl;
- R3 is selected from the group consisting of
- hydrogen and
- C1-6-alkyl;
- R4 is selected from the group consisting of
- halogen,
- C1-6-alkyl, and
- halogen-C1-6-alkoxy;
- R5 is —C(═O)—R6;
- and
- R6 is selected from the group consisting of
- heteroaryl,
- heteroaryl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl, C3-6-cycloalkyl, C3-6-cycloalkyl-C1-6-alkoxy, C3-6-cycloalkyl-C1-6-alkyl, C3-6-cycloalkyl-C2-6-alkynyl, C2-6-alkynyl-C1-6-alkoxy and C1-6-alkyl,
- C3-6-cycloalkyl,
- C3-6-cycloalkyl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, hydroxy, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl,
- heterocyclyl, and
- heterocyclyl substituted by 1-4 substituents individually selected from cyano, cyano-C1-6-alkyl, halogen, halogen-C1-6-alkoxy, halogen-C1-6-alkyl, C1-6-alkoxy, C1-6-alkoxy-C1-6-alkyl and C1-6-alkyl;
- or a pharmaceutically acceptable salt thereof
- and a pharmaceutically acceptable carrier.
24 more elements
Dependencies are inferred from the claim text.